This page shows the latest Price transparency news and features for those working in and with pharma, biotech and healthcare.
The main factors in pharma’s negative public perception included public drug price debates with the NHS, Brexit stockpiling uncertainties, executive pay, and a lack of transparency over clinical trials. ... At the same time, the Portland survey points
US among those in favour of price transparency. First proposed by Italy, the resolution has now been adopted at the World Health Assembly. ... The US, Japan and Switzerland agreed to support price transparency proposals, but opposed transparency in
Price transparency and choice: This topic is a book unto itself. ... It tells us what we know: that lack of price/cost transparency is choking our system, and everyone is worse off because of it.
to lower or impose drug price controls will not only reduce its ability to invest in research but will lead to fewer new therapies. ... He has also demanded greater price transparency from all healthcare providers, so that individuals can shop around for
We've spent much time debating and discussing the cost of therapies and how we can ensure price transparency in order to control costs.
If passed a new Bill would demand pharma show how product price tags are worked out. ... with a $94, 500 price tag, represent “important breakthroughs in biologic treatments for patients with these conditions”.
More from news
Approximately 1 fully matching, plus 8 partially matching documents found.
One of the advantages of using ASP as the benchmark for patient cost-sharing is the improved, though less than complete, price transparency that the metric provides. ... As an alternative, setting coinsurance for high-cost specialty therapies based on
level. It’s nothing short of a full-on legislative swarm. Half the states in the union (25) have pending price transparency laws, and at least 30 are crafting various forms ... Earlier this year, a group of physicians at the American Medical
Price controls now cover up to 30 per cent of the medicines sold in India. ... But he also urged transparency and greater dialogue over price capping.
Companies are facing extreme price cuts and strong competition in the off-patent sector. ... We will be looking at the Price Transparency Directive that is under review by the EC.
More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.
We are Evoke Mind ‘PLUS’ Matter. The ‘plus’ is important to us because we are all about offering more for...